Ukusebenza Okuphezulu Konyango lwe-CD7 CAR-T kwiZifo ze-B-Cell: Uphuhliso Olukhulu Kunyango Lomhlaza
Uphando lwamva nje lubonisa ukusebenza kakuhle kunye nokhuseleko lwe-CD7 CAR-T cell therapy ekunyangeni i-B-cell acute lymphoblastic leukemia (B-ALL) ephinde yabuyela kwi-relaxation okanye i-refractory kunye ne-T-cell lymphoblastic lymphoma (T-LBL). Olu phando luqhutywa yi-BIOOCUS ngokubambisana neSibhedlele iLu Daopei, lubonisa iziphumo ezithembisayo kwizigulana, zibonelela ngenye indlela enamandla endaweni ye-chemotherapy eqhelekileyo.
Kuphuhliso olunomdla kakhulu Unyango lomhlaza, I-BIOOCUS, ngokubambisana neSibhedlele iLu Daopei, ityhile uphando oluphambili malunga nokusetyenziswa konyango lwe-CD7 chimeric antigen receptor (CAR) T-cell. Le ndlela intsha, ejolise kwi-relapse okanye refractory B-cell acute lymphoblastic leukemia (B-ALL) kunye ne-T-cell lymphoblastic lymphoma (T-LBL), ibonisa ukusebenza kakuhle kunye nokhuseleko, nto leyo ephucula kakhulu iziphumo zezigulane.
Olu phononongo, olupapashwe kwijenali edumileyo, lubandakanya uthelekiso olufanayo lwezigulane ezifumana unyango lwe-CD7 CAR-T olulandelwe kukuhlanganiswa kwe-allogeneic hematopoietic stem cell transplantation (allo-HSCT) nxamnye nezo ziphathwe nge-chemotherapy ngaphambi kokufakelwa. Iziphumo zophando zibonisa ukuba izigulane ezifumene i-complement remission (CR) ngonyango lwe-CD7 CAR-T zineziphumo ezifanayo zokusinda ixesha elide nezo ziphathwe nge-chemotherapy eqhelekileyo. Okubalulekileyo kukuba, olu phononongo alufumananga ukwanda okukhulu kwiingxaki zasemva kokufakelwa, ezifana nesifo se-graft-versus-host (GVHD), usulelo, okanye ezinye iziganeko ezimbi.
Izinto eziphambili ezibalaseleyo kolu phononongo ziquka:
- Izinga lokuKhululwa ngokupheleleyo: Unyango lwe-CD7 CAR-T lubonise izinga elimangalisayo lokuxolelwa ngokupheleleyo, apho ngaphezulu kwe-97% yezigulana zisabela kakuhle kunyango.
- Iprofayili yoKhuseleko: Nangona indlela entsha yokusebenzisa unyango lwe-CAR-T, unyango lwalunyamezeleka kakuhle, kwaye iziphumo ebezingalindelekanga zazincinci kwaye akukho kunyuka kubalulekileyo kwi-GVHD ekumgangatho ophezulu okanye ezinye iingxaki ezinzima.
- Impumelelo Emva Kokufakelwa Isityalo: Izigulane ezisebenzisa i-allo-HSCT emva kokufumana unyango lwe-CR olusebenzisa i-CD7 CAR-T ziye zafumana ukusinda okunempilo (OS) kunye nokusinda okungenalo i-leukemia (LFS), okufana nonyango lwendabuko olusekelwe kwi-chemotherapy.
Olu phando lubonisa inqanaba elibalulekileyo kwicandelo le- Unyango lwe-Immunotherapy yomhlaza, inika ithemba kwizigulana ezineentlobo ze-leukemia kunye ne-lymphoma eziphinde zabuyela umva okanye ezingasasebenziyo. I-BIOOCUS isazimisele ukuphucula imida yonyango lwe-CAR-T, ibonelela ngezisombululo ezintsha kwizigulana eziye zasebenzisa iindlela zonyango eziqhelekileyo. Njengoko ihlabathi lizamkela ezi ndlela zonyango ziphambili, i-BIOOCUS iphambili ekuphuhliseni unyango oluzisa utshintsho lokwenyani kwiziphumo zezigulana.